ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

Standard

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. / Minner, Sarah Jane Pauline; Enodien, Malaika; Sirma, Hüseyin; Lübke, Andreas; Krohn, Antje; Mayer, Pascale S; Simon, Ronald; Tennstedt, Pierre; Müller, Julia; Scholz, Laura; Brase, Jan C; Liu, Alvin Y; Schlüter, Hartmut; Pantel, Klaus; Schumacher, Udo; Bokemeyer, Carsten; Steuber, Thomas; Graefen, Markus; Sauter, Guido; Schlomm, Thorsten.

in: CLIN CANCER RES, Jahrgang 17, Nr. 18, 18, 2011, S. 5878-5888.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{19804cd6539444e3b9a729532df3ae5e,
title = "ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.",
abstract = "About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression. The aim of this study was to determine whether clinical differences exist between ERG-positive and ERG-negative cancers in surgically treated patients not exposed to antihormonal therapy. A secondary aim was to search for differences between these tumor classes.",
keywords = "Adult, Humans, Male, Aged, Middle Aged, Aged, 80 and over, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Gene Rearrangement, Neoplasm Recurrence, Local/*diagnosis, Prostate-Specific Antigen/*blood, Prostatectomy, Prostatic Neoplasms/*diagnosis/genetics/metabolism/surgery, Receptors, Androgen/metabolism, Trans-Activators/*genetics/*metabolism, Tumor Markers, Biological/genetics/metabolism, Adult, Humans, Male, Aged, Middle Aged, Aged, 80 and over, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Gene Rearrangement, Neoplasm Recurrence, Local/*diagnosis, Prostate-Specific Antigen/*blood, Prostatectomy, Prostatic Neoplasms/*diagnosis/genetics/metabolism/surgery, Receptors, Androgen/metabolism, Trans-Activators/*genetics/*metabolism, Tumor Markers, Biological/genetics/metabolism",
author = "Minner, {Sarah Jane Pauline} and Malaika Enodien and H{\"u}seyin Sirma and Andreas L{\"u}bke and Antje Krohn and Mayer, {Pascale S} and Ronald Simon and Pierre Tennstedt and Julia M{\"u}ller and Laura Scholz and Brase, {Jan C} and Liu, {Alvin Y} and Hartmut Schl{\"u}ter and Klaus Pantel and Udo Schumacher and Carsten Bokemeyer and Thomas Steuber and Markus Graefen and Guido Sauter and Thorsten Schlomm",
year = "2011",
language = "English",
volume = "17",
pages = "5878--5888",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

RIS

TY - JOUR

T1 - ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

AU - Minner, Sarah Jane Pauline

AU - Enodien, Malaika

AU - Sirma, Hüseyin

AU - Lübke, Andreas

AU - Krohn, Antje

AU - Mayer, Pascale S

AU - Simon, Ronald

AU - Tennstedt, Pierre

AU - Müller, Julia

AU - Scholz, Laura

AU - Brase, Jan C

AU - Liu, Alvin Y

AU - Schlüter, Hartmut

AU - Pantel, Klaus

AU - Schumacher, Udo

AU - Bokemeyer, Carsten

AU - Steuber, Thomas

AU - Graefen, Markus

AU - Sauter, Guido

AU - Schlomm, Thorsten

PY - 2011

Y1 - 2011

N2 - About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression. The aim of this study was to determine whether clinical differences exist between ERG-positive and ERG-negative cancers in surgically treated patients not exposed to antihormonal therapy. A secondary aim was to search for differences between these tumor classes.

AB - About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression. The aim of this study was to determine whether clinical differences exist between ERG-positive and ERG-negative cancers in surgically treated patients not exposed to antihormonal therapy. A secondary aim was to search for differences between these tumor classes.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Aged, 80 and over

KW - Cell Line, Tumor

KW - Gene Expression Regulation, Neoplastic

KW - Gene Expression Profiling

KW - Gene Rearrangement

KW - Neoplasm Recurrence, Local/diagnosis

KW - Prostate-Specific Antigen/blood

KW - Prostatectomy

KW - Prostatic Neoplasms/diagnosis/genetics/metabolism/surgery

KW - Receptors, Androgen/metabolism

KW - Trans-Activators/genetics/metabolism

KW - Tumor Markers, Biological/genetics/metabolism

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Aged, 80 and over

KW - Cell Line, Tumor

KW - Gene Expression Regulation, Neoplastic

KW - Gene Expression Profiling

KW - Gene Rearrangement

KW - Neoplasm Recurrence, Local/diagnosis

KW - Prostate-Specific Antigen/blood

KW - Prostatectomy

KW - Prostatic Neoplasms/diagnosis/genetics/metabolism/surgery

KW - Receptors, Androgen/metabolism

KW - Trans-Activators/genetics/metabolism

KW - Tumor Markers, Biological/genetics/metabolism

M3 - SCORING: Journal article

VL - 17

SP - 5878

EP - 5888

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 18

M1 - 18

ER -